With the global supply of Covid-19 vaccine still woefully inadequate, vaccine makers are scouring the pharmaceutical landscape for partners to ramp up manufacturing, and civil society groups are pressing politicians to waive intellectual property protections in a bid to spur still more production.
Problem, Solution, SitRep, or ?:
Recent Comments